Clinical logistics · ending well
The exit interview: how to stop GLP-1 therapy well — medically, financially, and psychologically
Stopping is a phase of therapy, not an escape from it, and doing it well has three files. Medical: the withdrawal trials are unambiguous — on average people regain a large share of lost weight within a year of stopping — so an exit plan is really a maintenance plan: prescriber-guided (there’s no official taper protocol; some clinicians step doses down or stretch intervals, evidence still thin), with the behavioral scaffold pre-hardened and a re-entry threshold written down before you need it. Pregnancy planning is its own lane with label rules — semaglutide’s label calls for stopping at least two months before a planned conception, and tirzepatide carries the oral-contraceptive backup-method note around initiation and dose steps — timelines your prescriber owns. Financial: cancel per the terms you saved — written notice, confirmation captured, final-shipment timing settled, refund taxonomy consulted — because exits are where billing behavior shows its true face. Psychological: keep the identity, retire the tool — details below, plus the re-entry file that makes a future restart cheap instead of chaotic.
Legitimate exits — the honest taxonomy
Goal-reached maintenance attempts — the plateau reframe taken seriously: some patients, especially after long stability, trial an unmedicated hold with eyes open about the regain averages. Pregnancy planning — label-governed timelines (the two-month semaglutide washout; tirzepatide’s contraception notes) that convert “someday” conversations into calendar math with your prescriber. Finances — real, and worth auditing before surrendering to: the renewal review plus the audited floors ($119/$139; compounded, not FDA-approved) have rescued many “I can’t afford this” exits into “I was overpaying” stays. Side-effect ceilings — after the sibling-molecule option is genuinely explored. Surgery and procedure holds — usually pauses wearing exit costumes; the perioperative file covers them. Naming your exit’s category out loud matters, because each has a different correct next paragraph.
The medical exit — what the evidence and labels actually say
The withdrawal data deserves plain language: in the major discontinuation studies, participants regained on average a substantial fraction — commonly summarized as around half or more — of lost weight within a year off medication, with cardiometabolic markers drifting back alongside. That’s not a threat; it’s a planning parameter: it says the unmedicated hold is an active project, not a finish line. The taper question is honestly unsettled — no label specifies a discontinuation schedule, some prescribers step down doses or stretch intervals to test stability on the way out, and comparative evidence remains thin; what’s yours is the conversation, not the improvisation. Pre-harden the scaffold before the last dose, not after: protein targets, resistance training, weigh-in cadence — the trial behaviors that were doing quiet work all along become the whole workforce. And set the re-entry threshold in writing while calm: “if I regain X pounds or Y symptoms return by date Z, I restart the conversation” — thresholds chosen in advance get honored; thresholds improvised during regain get negotiated downward by the same brain that’s regaining.
The paperwork exit — where providers show you who they are
Execute the cancellation like the audit it secretly is: re-read the current terms (they may have drifted since signup — another renewal-review artifact), give notice in the required channel in writing, capture the confirmation, and settle final-shipment logic explicitly — whether a paid-for final vial ships, and when billing truly stops. The consumer-protection floor is on your side: negative-option rules and state auto-renewal laws require functional cancellation paths, and a provider that makes leaving hard has told you everything retroactively. Prepaid blocks: consult the taxonomy before assuming forfeiture — some plans pro-rate, some don’t, and the difference is a paragraph you can quote. Keep the artifacts (terms PDF, confirmation email, final statement) in the same folder as your medical records; exits generate disputes at a higher rate than any other subscription moment, and documented customers win them.
The identity exit — keep the person, retire the tool
Months of therapy quietly rebuild identity — the person who cooks differently, moves differently, hears less food noise — and a common stopping-time error is bundling the identity with the medication and discarding both. The useful frame: the medication was scaffolding; the structure it helped build is yours. Expect appetite’s return to feel loud after the quiet (it’s the old normal, recontextualized), expect the scale to demand the emotional regulation you’ve been practicing, and expect week six to test the plan more than week one. The community’s stopping threads are genuinely strong on this territory — lived texture about the off-ramp — filtered as always. And permission, stated plainly because it helps: restarting later isn’t failure; it’s using a chronic-condition tool the way chronic-condition tools work.
The re-entry file — make your future restart cheap
Before the portal access lapses, export: dose history and titration dates, side-effect notes, weights, labs, and the pharmacy names that served you well — the packet that turns a future restart from re-onboarding into resumption. Note the field’s state on your way out (which providers, which verified prices — today’s dated index beats next year’s memory), and know the restart reality: after a long gap, titration restarts low per labels, so the re-entry corridor looks like the first one — plan its timeline accordingly. File it all next to the written re-entry threshold, and the exit is complete: reversible, documented, and yours.
FAQ
Do you regain weight after stopping GLP-1 medication?
On average, discontinuation studies show a large share — commonly around half or more — of lost weight returning within a year, which is why exits are planned as active maintenance projects with pre-set re-entry thresholds.
Should GLP-1s be tapered or stopped cold?
No official taper exists; some prescribers step down or stretch intervals while evidence remains thin — it’s a clinical conversation, not a protocol you improvise.
When should semaglutide be stopped before pregnancy?
The label calls for discontinuation at least two months before a planned pregnancy; tirzepatide carries oral-contraceptive backup notes around initiation and dose increases — both are prescriber-owned timelines.